427 material Form 8-K filings that 376 companies we cover made with the SEC in September 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Ultra Clean Holdings entered into an Eighth Amendment to its Credit Agreement with Barclays Bank PLC, as administrative agent, dated September 15, 2025. The amendment lowers the interest rate on the term loan facility by 0.5% per annum. The filing does not state the loan balance or the dollar savings, so the effect on shareholders is not quantified.
Eighth Amendment dated as of September 15, 2025, to the Credit Agreement dated August 27, 2018
Term loan facility interest rate reduced by 0.5% per annum
Barclays Bank PLC is administrative agent; full text filed as Exhibit 10.1
Insulet said Flavia Pease, currently a director and former CFO of Charles River Laboratories, will succeed Ana Chadwick as Executive Vice President and Chief Financial Officer effective September 30, 2025, and Ms. Chadwick will stay on as a Senior Advisor. The company also said it expects to exceed its previously issued third quarter 2025 total revenue growth guidance, driven by strong new customer starts in the U.S. and international markets.
Flavia Pease becomes CFO effective September 30, 2025; she will resign from the Board on starting employment.
Ana Chadwick remains with the company as a Senior Advisor and is expected to receive severance and a one-time cash payment tied to equity vesting May 1, 2026.
Pease's offer includes a $1,325,000 cash sign-on award and a $3,000,000 target equity sign-on award, plus a $762,500 prorated annual equity award and a $715,000 base salary.
Insulet expects to exceed prior Q3 2025 total revenue growth guidance and will report full results and a full-year outlook update on November 6, 2025.
Ferguson reported fourth-quarter sales of $8.5 billion, up 6.9%, and diluted EPS of $3.55 versus $2.23 a year earlier, with adjusted EPS of $3.48, up 16.8%. The company also said it will change its fiscal year-end from July 31 to December 31, with a five-month transition period from August 1 to December 31, 2025, and gave calendar 2025 guidance of mid-single digit revenue growth and a 9.2% to 9.6% adjusted operating margin.
Q4 net sales $8.5 billion, up 6.9%; organic revenue up 5.8%; reported operating profit $925 million, up 14.1%
Full-year sales $30.8 billion, up 3.8%; reported operating profit $2.6 billion, down 1.7%; adjusted diluted EPS $9.94, up 2.6%
Calendar 2025 guidance: mid-single digit revenue growth and adjusted operating margin of 9.2% to 9.6%
Next earnings release December 9, 2025; 2026 annual meeting set for April 30, 2026; shareholder proposal deadline November 16, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.